Genetics and the PNPLA6 Spectrum

When a child is diagnosed with Oliver-McFarlane Syndrome (OMS), the focus often turns to a specific gene called PNPLA6. Understanding the genetics behind OMS can help you make sense of why the syndrome affects so many different parts of the body, from the eyes to the hair to the growth hormones.

The PNPLA6 Gene and Its Role

The PNPLA6 gene is responsible for providing the instructions to create a protein called neuropathy target esterase (NTE) ^[1]. This protein lives inside a part of the cell called the endoplasmic reticulum (ER), which functions like a factory for the cell ^[2].

NTE belongs to a family of enzymes called phospholipases. Its primary job is to help manage the balance of fats (lipids) within the cell’s membranes, specifically by breaking down certain phospholipids called phosphatidylcholine and lysophosphatidylcholine ^[3][2]. When the PNPLA6 gene has a mutation, the NTE protein may not work correctly, leading to an imbalance of these fats ^[4]. This imbalance is thought to disrupt and damage many different types of cells, including:

• Neurons: Leading to neurological symptoms ^[5].
• Retinal Cells: Causing the vision loss seen in chorioretinal degeneration ^[6].
• Pituitary Cells: Affecting the production of essential growth and development hormones ^[7].

How OMS Is Inherited

OMS is an autosomal recessive disorder ^[8]. Every person has two copies of the PNPLA6 gene—one inherited from their mother and one from their father. For a child to have OMS, both copies of the gene must have a “pathogenic” (disease-causing) mutation ^[1].

Understanding Your Status as a Parent

In most cases, parents of a child with OMS are carriers. This means they have one mutated copy of the gene and one healthy copy ^[8]. Because the healthy copy can still produce enough NTE protein for the body to function normally, carriers typically show no symptoms of the syndrome.

When two carriers have a child together, there is:

• A 25% chance with each pregnancy that the child will inherit both mutated genes and have the syndrome.
• A 50% chance the child will be a carrier like their parents.
• A 25% chance the child will inherit two healthy genes ^[8].

Understanding Your Genetic Report and Compound Heterozygosity

While some children inherit the exact same mutation from both parents, it is very common in OMS for a child to have compound heterozygosity ^[9]. This means they have two different types of mutations in the PNPLA6 gene—one unique mistake from the mother and a different unique mistake from the father ^[8].

A genetic report distinguishes between a “pathogenic/likely pathogenic variant” (known to cause disease) and a “variant of uncertain significance” (VUS). A VUS generally does not establish the diagnosis by itself. To confirm the diagnosis, doctors often perform segregation analysis. This is a process where the parents are also tested to ensure that the child’s two mutations actually came from one each, rather than both being on the same copy of the gene (establishing phase). While parental testing establishes phase, it does not by itself prove a VUS is pathogenic ^[1][8].

The PNPLA6 Spectrum

One of the most complex aspects of this genetics story is that mutations in the PNPLA6 gene do not always cause Oliver-McFarlane Syndrome. Instead, they cause a “spectrum” of related disorders. Depending on the specific mutations and how much they reduce the activity of the NTE protein, a person may be diagnosed with one of five commonly described PNPLA6-related phenotypes:

1. Oliver-McFarlane Syndrome (OMS): Focused on hair, eye, and growth issues ^[10].
2. Boucher-Neuhäuser Syndrome (BNS): Involves ataxia (balance issues), eye disease, and hormone deficiencies ^[11].
3. Gordon-Holmes Syndrome (GHS): Characterized by balance issues and hormone deficiencies affecting puberty ^[11].
4. Laurence-Moon Syndrome (LMS): A complex syndrome involving intellectual disability, eye disease, and spasticity ^[12].
5. Spastic Paraplegia Type 39 (SPG39): Primarily affects the nerves and muscles in the legs, leading to stiffness and weakness ^[12].

It is important to remember that these “labels” are overlapping clinical descriptions, not a predictable progression. Monitoring should follow the person’s actual symptoms rather than the names of every related disorder ^[13].

Predicting Severity: The Genotype-Phenotype Puzzle

Parents often ask if their child’s specific mutations can predict how severe their symptoms will be. This is known as genotype-phenotype correlation. In the case of PNPLA6, this prediction is very difficult ^[10].

While there are some general trends—for example, mutations that almost completely disable the NTE protein are more likely to be linked to severe vision and hormone problems—the correlation is not perfect ^[1][14]. Even siblings with the exact same mutations can have different symptoms or varying degrees of severity ^[13][15]. This variability suggests that other genetic factors or environmental influences may also play a role in how the syndrome develops in each individual ^[12].

Because of this, your child’s care will be based on their specific symptoms rather than just their genetic report. Regular monitoring of their eyes, growth, and development remains the best way to manage their unique needs.